new glp-1 Ro Launches Wegovy® Pill Through Integration with Novo Nordisk America Has a New GLP-1
Description
In a meta-analysis of 4 studies (STEP-HFpEF, STEP-HFpEF DM, SELECT, and FLOW) 3743 patients had heart failure with preserved ejection fraction
In both cases, there are important compliance and PBM contractual considerations that need to be explored and fully vetted as part of decision making
We show you exactly how we weight each category and why
T2DM is a metabolic disease caused by acquired endocrine disorders
You understand that clinical trial outcomes do not constitute guarantees of effect
Nima Alamdari Jennifer Martin-Biggers PhD, MS, RD and a very special guest in the field
